

REMARKS


This paper is filed to amend US Application No. 10/582,534, which is a 35 U.S.C. §371 national application based on international application no. PCT/US2004/042045, filed December 15, 2004, claiming priority to US provisional application 60/529,822, filed December 16, 2003.

The claims and specification have been amended to include the SEQ ID numbers of sequences of naturally occurring amino acids, in accordance with 37 C.F.R. §1.821.

Applicants request entry of the substitute specification that accompanies these papers, pursuant to 37 C.F.R. §1.125(b). A marked-up copy of the substitute specification showing the matter being added to and the matter being deleted from the specification of record is included herewith. Deletions are indicated by ~~strikethrough~~, additions by underlining. Applicants through their attorneys state that no new matter is presented therein.

Entry of the foregoing amendments and examination of the claims as amended are requested.

Respectfully submitted,



Leon R. Yankwich, Reg. No. 30,237
Michael R. Wesolowski, Reg. No. 50,944
Attorneys for Applicant

Direct all correspondence to:


Alan F. Feeney, Esq.
Biomeasure, Incorporated
27 Maple Street
Milford, MA 01757-3650
telephone: (508) 478-0144
telecopier: (508) 473-3531

Certificate of Mailing

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service under 37 CFR 1.8, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

1/30/2009

date



Meghan F. McFadden



ANALOGUES OF GLP-1

Background of the Invention

5 This application is a United States national stage filing under 35 U.S.C. §371 of
international (PCT) application No. PCT/US2004/042045, filed December 15, 2004 and
designating the US, which application claims priority to US provisional application 60/529,822
filed December 16, 2003.

10 The present invention is directed to peptide analogues of glucagon-like peptide-1, the
pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat
mammals and to pharmaceutical compositions useful therefor comprising said analogues.

15 Glucagon-like peptide-1 (7-36) amide (GLP-1) is synthesized in the intestinal L-cells by
tissue-specific post-translational processing of the glucagon precursor preproglucagon
(Varndell, J.M., et al., J. Histochem Cytochem, 1985:33:1080-6) and is released into the
circulation in response to a meal. The plasma concentration of GLP-1 rises from a fasting level
of approximately 15 pmol/L to a peak postprandial level of 40 pmol/L. It has been demonstrated
that, for a given rise in plasma glucose concentration, the increase in plasma insulin is
approximately threefold greater when glucose is administered orally compared with
intravenously (Kreymann, B., et al., Lancet 1987:2, 1300-4). This alimentary enhancement of
20 insulin release, known as the incretin effect, is primarily humoral and GLP-1 is now thought to
be the most potent physiological incretin in humans. In addition to the insulinotropic effect, GLP-
1 suppresses glucagon secretion, delays gastric emptying (Wettergren A., et al., Dig Dis Sci
1993:38:665-73) and may enhance peripheral glucose disposal (D'Alessio, D.A. et al., J. Clin
Invest 1994:93:2293-6).

25 In 1994, the therapeutic potential of GLP-1 was suggested following the observation that
a single subcutaneous (s/c) dose of GLP-1 could completely normalize postprandial glucose
levels in patients with non-insulin-dependent diabetes mellitus (NIDDM) (Gutniak, M.K., et al.,
Diabetes Care 1994:17:1039-44). This effect was thought to be mediated both by increased
insulin release and by a reduction in glucagon secretion. Furthermore, an intravenous infusion
30 of GLP-1 has been shown to delay postprandial gastric emptying in patients with NIDDM
(Williams, B., et al., J. Clin Endo Metab 1996:81:327-32). Unlike sulphonylureas, the
insulinotropic action of GLP-1 is dependent on plasma glucose concentration (Holz, G.G. 4th, et
al., Nature 1993:361:362-5). Thus, the loss of GLP-1-mediated insulin release at low plasma
glucose concentration protects against severe hypoglycemia. This combination of actions gives


GLP-1 unique potential therapeutic advantages over other agents currently used to treat NIDDM.

Numerous studies have shown that when given to healthy subjects, GLP-1 potently influences glycemic levels as well as insulin and glucagon concentrations (Orskov, C, Diabetologia 35:701-711, 1992; Holst, J.J., et al., Potential of GLP-1 in diabetes management in Glucagon III, Handbook of Experimental Pharmacology, Lefebvre PJ, Ed. Berlin, Springer Verlag, 1996, p. 311-326), effects which are glucose dependent (Kreymann, B., et al., Lancet ii:1300-1304, 1987; Weir, G.C., et al., Diabetes 38:338-342, 1989). Moreover, it is also effective in patients with diabetes (Gutniak, M., N. Engl J Med 226:1316-1322, 1992; Nathan, D.M., et al., Diabetes Care 15:270-276, 1992), normalizing blood glucose levels in type 2 diabetic subjects (Nauck, M.A., et al., Diabetologia 36:741-744, 1993), and improving glycemic control in type 1 patients (Creutzfeldt, W.O., et al., Diabetes Care 19:580-586, 1996), raising the possibility of its use as a therapeutic agent.

GLP-1 is, however, metabolically unstable, having a plasma half-life ($t_{1/2}$) of only 1-2 min *in vivo*. Exogenously administered GLP-1 is also rapidly degraded (Deacon, C.F., et al., Diabetes 44:1126-1131, 1995). This metabolic instability limits the therapeutic potential of native GLP-1. Hence, there is a need for GLP-1 analogues that are more active and/or are more metabolically stable than native GLP-1.

Summary of the Invention

In one aspect the invention features a compound according to formula (I),



wherein

A^7 is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;

A^8 is Ala, β -Ala, Gly, Ser, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;

A^9 is Glu, N-Me-Glu, N-Me-Asp or Asp;

A^{10} is Gly, Acc, β -Ala or Aib;

A^{11} is Thr or Ser;

A^{12} is Phe, Acc, Aic, Aib, 2-Pal, 3-Pal, 4-Pal, 1Nal, 2Nal, Cha, Trp or ($X^6, X^7, X^8, X^9, X^{10}$)Phe;

- A¹³ is Thr or Ser;
A¹⁴ is Ser or Aib;
A¹⁵ is Asp or Glu;
A¹⁶ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;
5 A¹⁷ is Ser, Aib or Thr;
A¹⁸ is Ser, Lys or Thr;
A¹⁹ is Tyr, Cha, Phe, 2-Pal, 3-Pal, 4-Pal, 1Nal, 2Nal, Acc or (X⁶,X⁷,X⁸,X⁹,X¹⁰)Phe;
A²⁰ is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or (X⁶,X⁷,X⁸,X⁹,X¹⁰)Phe;
A²¹ is Glu or Asp;
10 A²² is Gly, Acc, β -Ala, Glu or Aib;
A²³ is Gln, Asp, Asn or Glu;
A²⁴ is Ala, Aib, Val, Abu, Tle or Acc;
A²⁵ is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O) or HN-CH((CH₂)_e-X³)-C(O);
15 A²⁶ is Lys, Arg, hArg, Orn, Lys(N^E-decanoyl)), HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O) or HN-CH((CH₂)_e-X³)-C(O);
A²⁷ is Glu, Asp, Leu, Aib or Lys;
A²⁸ is Phe, 2-Pal, 3-Pal, 4-Pal, 1Nal, 2Nal, (X⁶,X⁷,X⁸,X⁹,X¹⁰)Phe, Aic, Acc, Aib, Cha or Trp;
A²⁹ is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;
20 A³⁰ is Ala, Aib or Acc;
A³¹ is Trp, 2-Pal, 3-Pal, 4-Pal, 1Nal, 2Nal, Phe, Acc, Aib, (X⁶,X⁷,X⁸,X⁹,X¹⁰)Phe or Cha;
A³² is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, (X⁶,X⁷,X⁸,X⁹,X¹⁰)Phe or Ala;
A³³ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or (X⁶,X⁷,X⁸,X⁹,X¹⁰)Phe;
A³⁴ is Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O) or HN-CH((CH₂)_e-X³)-C(O);
25 A³⁵ is β -Ala, D-Ala, Gaba, Ava, HN-(CH₂)_m-C(O), Aib, Acc, D-Arg or a D-amino acid;
A³⁶ is L- or D-Arg, D- or L-Lys, or Lys(N^E-decanoyl) or Lys(N^E-dodecanoyl) or D- or L-hArg, D- or L-Orn or HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O), or HN-CH((CH₂)_e-X³)-C(O);
A³⁷ is Gly, β -Ala, Gaba, Aib, Acc, Act, Apc, Aun, Ava, Pro, Dhp, Dmt, Pip, ~~3-Hpr~~, ~~4-Hpr~~, L- or D- Arg, L- or D- Asp or Glu, Lys(N^E-decanoyl), Lys(N^E-dodecanoyl), Lys(N^E-
30 octanoyl), Lys(N^E-tetradecanoyl), or Ser(O-decanoyl);
A³⁸ is D- or L- His, L- or D-Ala, Asn, Gln, Ser, Thr, Acc, Ado, Aib, Apc, Act, Arg, Ava, Gly, β -Ala, Gaba, or HN-(CH₂)_s-C(O);

A³⁹ is D- or L- His, L- or D-Ala, Asn, Gln, Ser, Thr, Acc, Ado, Aib, Apc, Act, Arg, Aun, Gly, β-Ala, Gaba, Lys(N^e-octanoyl), HN-(CH₂)₅-C(O), or deleted;

R¹ is OH, NH₂; (C₁-C₃₀)alkoxy, or NH-X²-CH₂-Z⁰, wherein X² is a (C₀-C₂), (C₄-C₉) or (C₁₁-C₁₉)hydrocarbon moiety and Z⁰ is H, OH, CO₂H or CONH₂;

5 X³ is
$$X^4-N\text{---}\text{[piperidine ring]---}N\text{---}(\text{CH}_2)_f\text{---CH}_3 \quad \text{---NH-C(O)-CH}_2\text{---N}\text{---}\text{[piperidine ring]---}N\text{---}(\text{CH}_2)_2\text{---NH-C(O)-R}^{13}$$
,
 or -C(O)-NHR¹², wherein X⁴ is, independently for each occurrence, -C(O)-, -NH-C(O)- or -CH₂-,
 and wherein f is, independently for each occurrence, an integer from 1 to 29 inclusive;
 each of R² and R³ is independently selected from the group consisting of H, (C₁-C₃₀)alkyl, (C₂-
 C₃₀)alkenyl, optionally substituted phenyl(C₁-C₃₀)alkyl, optionally substituted naphthyl(C₁-
 10 C₃₀)alkyl, hydroxy(C₁-C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl, hydroxyphenyl(C₁-C₃₀)alkyl, and
 hydroxynaphthyl(C₁-C₃₀)alkyl;

wherein the phenyl group of said optionally substituted phenyl(C₁-C₃₀)alkyl moiety, and
 said naphthyl group of said optionally substituted naphthyl(C₁-C₃₀)alkyl moiety each is,
 independently for each occurrence, substituted with 1 or more substituents selected,
 15 independently for each occurrence, from the group consisting of halo, OH, NH₂, NO₂ and CN;

or one of R² and R³ is
$$(\text{CH}_3)_2\text{---N---}\overset{\uparrow}{\text{C}}^+=\text{N}(\text{CH}_3)_2$$
, (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl, C(O)X⁵,

$$Y(\text{CH}_2)_r\text{---N}\text{---}\text{[piperidine ring]---}N\text{---}(\text{CH}_2)_q\text{---SO}_2\text{---} \quad Y(\text{CH}_2)_r\text{---N}\text{---}\text{[piperidine ring]---}N\text{---}(\text{CH}_2)_q\text{---CO---}$$
, or ; wherein Y is H, OH or
 NH₂; r is 0 to 4; q is 0 to 4; and X⁵ is (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, phenyl(C₁-C₃₀)alkyl,
 naphthyl(C₁-C₃₀)alkyl, hydroxy(C₁-C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl, hydroxyphenyl(C₁-C₃₀)alkyl
 20 or hydroxynaphthyl(C₁-C₃₀)alkyl;

X⁶, X⁷, X⁸, X⁹, X¹⁰ for each occurrence is independently selected from the group consisting of H,
 (C₁-C₆)alkyl, OH, OR⁴, NO₂, CN, and halo;

R⁴ is (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, phenyl(C₁-C₃₀)alkyl, naphthyl(C₁-C₃₀)alkyl, hydroxy(C₁-
 C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl, hydroxyphenyl(C₁-C₃₀)alkyl or hydroxynaphthyl(C₁-C₃₀)alkyl;


e is, independently for each occurrence, an integer from 1 to 4 inclusive;

m is, independently for each occurrence, an integer from 5 to 24 inclusive;

s is, independently for each occurrence, an integer from 5 to 10 or from 12 to 20 inclusive;

n is, independently for each occurrence, an integer from 1 to 5, inclusive;

each of R¹⁰ and R¹¹ is, independently for each occurrence, H, (C₁-C₃₀)alkyl, (C₁-C₃₀)acyl, (C₁-




C₃₀)alkylsulfonyl, -C((NH)(NH₂)) or

; and

- 5 R¹² and R¹³ each is, independently for each occurrence, (C₁-C₃₀)alkyl;
 provided that:

when A⁷ is Ura, Paa or Pta, then R² and R³ are deleted;

when R¹⁰ is (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl, -C((NH)(NH₂)) or



- 10 , then R¹¹ is H or (C₁-C₃₀)alkyl;

(i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-38 or -39)NH₂ or hGLP-1(7-38 or -39)OH;

(ii) a compound of formula (I) is not an analogue of hGLP-1(7-38 or -39)NH₂ or hGLP-1(7-38, or -39)OH wherein a single position has been substituted by Ala;

- 15 (iii) a compound of formula (I) is not (Arg^{26,34}, Lys³⁸)hGLP-1(7-38)-E, (Lys²⁶(N^ε-alkanoyl))hGLP-1(7-38)-E, (Lys³⁴(N^ε-alkanoyl))hGLP-1(7-38)-E, (Lys^{26,34}-bis(N^ε-alkanoyl))hGLP-1(7-38)-E, (Arg²⁶, Lys³⁴(N^ε-alkanoyl))hGLP-1(8-38)-E, (Arg^{26,34}, Lys³⁶(N^ε-alkanoyl))hGLP-1(7-38)-E or (Arg^{26,34}, Lys³⁸(N^ε-alkanoyl))hGLP-1(7-38)-E, wherein E is -OH or -NH₂;

- 20 (iv) a compound of formula (I) is not Z¹-hGLP-1(7-38)-OH, Z¹-hGLP-1(7-38)-NH₂; wherein Z¹ is selected from the group consisting of:

(a) (Arg²⁶), (Arg³⁴), (Arg^{26,34}), (Lys³⁶), (Arg²⁶, Lys³⁶), (Arg³⁴, Lys³⁶), (D-Lys³⁶), (Arg³⁶), (D-Arg³⁶), (Arg^{26,34}, Lys³⁶) or (Arg^{26,36}, Lys³⁴);

(b) (Asp²¹);

(c) at least one of (Aib⁸), (D-Ala⁸) and (Asp⁹); and

- 25 (d) (Tyr⁷), (N-acyl-His⁷), (N-alkyl-His⁷), (N-acyl-D-His⁷) or (N-alkyl-D-His⁷); and

(v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d); or a pharmaceutically acceptable salt thereof.


A preferred group of compounds of the immediately foregoing compound is where A¹¹ is Thr; A¹³ is Thr; A¹⁵ is Asp; A¹⁷ is Ser; A¹⁸ is Ser or Lys; A²¹ is Glu; A²³ is Gln or Glu; A²⁷ is Glu, Leu, Aib or Lys; and A³¹ is Trp, Phe, 1Nal or 2Nal; or a pharmaceutically acceptable salt thereof.

5 A preferred group of compounds of the immediately foregoing group of compounds is where A⁹ is Glu, N-Me-Glu or N-Me-Asp; A¹² is Phe, Acc, 1Nal, 2Nal, or Aic; A¹⁶ is Val, Acc or Aib; A¹⁹ is Tyr, 1Nal or 2Nal; A²⁰ is Leu, Acc or Cha; A²⁴ is Ala, Aib or Acc; A²⁵ is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O) or HN-CH((CH₂)_e-X³)-C(O); A²⁸ is Phe, 1Nal or 2Nal; A²⁹ is Ile or Acc; A³⁰ is Ala or Aib; A³² is Leu, Acc or Cha; and A³³ is Val, Lys or Acc; or a pharmaceutically acceptable salt thereof.


10 A preferred group of compounds of the immediately foregoing group of compounds is where A⁸ is Ala, Gly, Ser, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A¹⁰ is Gly; A¹² is Phe, 1Nal, 2Nal, A6c or A5c; A¹⁶ is Val, A6c or A5c; A²⁰ is Leu, A6c, A5c or Cha; A²² is Gly, β-Ala, Glu or Aib; A²⁴ is Ala or Aib; A²⁹ is Ile, A6c or A5c; A³² is Leu, A6c, A5c or Cha; A³³ is Val, Lys, A6c or A5c; A³⁵ is Aib, β-Ala, Ado, A6c, A5c, D-Arg or Acc; A³⁷ is Gly, Aib, β-Ala, D-
 15 Ala, Pro, Asp, Aun or D-Asp; A³⁸ is D- or L- His, Asn, Ser, Apc, Act, Gly, β-Ala or Gaba; and A³⁹ is Ser, Thr or Aib; or a pharmaceutically acceptable salt thereof.

A preferred group of compounds of the immediately foregoing group of compounds is where X⁴ for each occurrence is -C(O)-; and R¹ is OH or NH₂; or a pharmaceutically acceptable salt thereof.

20 A preferred group of compounds of the immediately foregoing group of compounds or a pharmaceutically acceptable salt thereof is where R² is H and R³ is (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl,




25 A preferred group of the compounds of the immediately foregoing group of compounds or a pharmaceutically acceptable salt thereof, is where R¹⁰ is (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl or



, and R¹¹ is H.


A preferred group of the compounds of the immediately foregoing group of compounds or a pharmaceutically acceptable salt thereof, is where R¹⁰ is (C₄-C₂₀)acyl, (C₄-C₂₀)alkylsulfonyl or



5


A preferred compound of the formula (I) is where A⁸ is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A¹⁰ is Gly; A¹² is Phe, 1NaI, 2NaI, A6c or A5c; A¹⁶ is Val, A6c or A5c; A²⁰ is Leu, A6c, A5c or Cha; A²² is Gly, β-Ala, Glu or Aib; A²⁴ is Ala or Aib; A²⁹ is Ile, A6c or A5c; A³² is Leu, A6c, A5c or Cha; A³³ is Val, Lys, A6c or A5c; A³⁵ is Aib, β-Ala, Ado, A6c, A5c or D-Arg; and A³⁷ is Gly, Aib, β-Ala, D-Ala, Pro or D-Asp; A³⁸ is D- or L- His, Asn, Ser, Gly, β-Ala or Gaba; and A³⁹ is Ser, or deleted; X⁴ for each occurrence is -C(O)-; e for each occurrence is independently 1 or 2; R¹ is OH or NH₂; R¹⁰ is (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl or

10



, and R¹¹ is H; or a pharmaceutically acceptable salt thereof.

15 More preferred of the immediately foregoing compounds is where R¹⁰ is (C₄-C₂₀)acyl,



(C₄-C₂₀)alkylsulfonyl or , or a pharmaceutically acceptable salt thereof.

A more preferred compound of formula (I) is where said compound is the pharmaceutically acceptable salt thereof.

20 More preferred of the immediately foregoing group of compounds is a compound of the formula:

(Aib^{8,35}, Arg^{26,34}, Phe³¹, Pro³⁷, Ser^{38,39})hGLP-1(7-39)-NH₂; (SEQ ID NO:1)

(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Asn³⁸)hGLP-1(7-38)-NH₂; (SEQ ID NO:2)


(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Ser³⁸)hGLP-1(7-38)-NH₂; (SEQ ID NO:3)

25 (Aib^{8,35,37}, Gaba³⁸)hGLP-1(7-38)-NH₂; (SEQ ID NO:4)

- (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:5)
(Aib^{8,35}, Arg^{26,34}, Phe³¹, β-Ala³⁷, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:6)
(Aib^{8,35,37}, Arg^{26,34}, D-His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:7)
(Aib^{8,35,37}, β-Ala³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:8)
5 (Aib^{8,35}, Arg^{26,34}, β-Ala³⁷, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:9)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Gly³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:10)
(Aib^{8,35,37}, Arg^{26,34}, Gly³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:11)
(Aib^{8,35,37}, Arg^{26,34}, β-Ala³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:12)
(Aib^{8,35,37}, Arg^{26,34}, Gaba³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:13)
10 (Aib^{8,35,37}, Arg³⁴, Phe³¹, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:14)
(Aib^{8,35,37}, Arg^{26,34}, His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:15)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Gaba³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:16)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Ava³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:17)
(Aib^{8,35,37}, Arg^{26,34}, Ava³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:18)
15 (Aib^{8,35,37}, Arg³⁴, Phe³¹, D-His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:19)
(Aib^{8,35,37}, Arg³⁴, Phe³¹, Gly³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:20)
(Aib^{8,35,37}, Gly³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:21)
(Aib^{8,35,37}, Arg^{26,34}, Phe³¹, D-His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:22)
(Aib^{8,35}, Arg^{26,34}, Phe³¹, β-Ala³⁷, D-His³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:23)
20 (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, β-Ala³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:24)
(Aib^{8,35}, Arg^{26,34}, Phe³¹, β-Ala^{37,38})hGLP-1(7-38) NH₂; (SEQ ID NO:25)
(Aib^{8,35,37}, Arg³⁴, Phe³¹, β-Ala³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:26) or
(Aib^{8,35,37}, Arg³⁴, Phe³¹, Gaba³⁸)hGLP-1(7-38) NH₂; (SEQ ID NO:27)
or a pharmaceutically acceptable salt thereof.


25

- In another aspect, the present invention is directed to a compound according to formula
30 (II),



(II)

wherein



- A^8 is Ala, β -Ala, Gly, Ser, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;
- 10 A^9 is Glu, N-Me-Glu, N-Me-Asp or Asp;
- A^{10} is Gly, Acc, β -Ala or Aib;
- A^{11} is Thr or Ser;
- A^{12} is Phe, Acc, Aic, Aib, 2-Pal, 3-Pal, 4-Pal, 1Nal, 2Nal, Cha, Trp or $(X^6, X^7, X^8, X^9, X^{10})$ Phe;
- A^{13} is Thr or Ser;
- 15 A^{14} is Ser or Aib;
- A^{15} is Asp or Glu;
- A^{16} is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;
- A^{17} is Ser, Aib or Thr;
- A^{18} is Ser, Lys or Thr;
- 20 A^{19} is Tyr, Cha, Phe, 2-Pal, 3-Pal, 4-Pal, 1Nal, 2Nal, Acc or $(X^6, X^7, X^8, X^9, X^{10})$ Phe;
- A^{20} is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or $(X^6, X^7, X^8, X^9, X^{10})$ Phe;
- A^{21} is Glu or Asp;
- A^{22} is Gly, Acc, β -Ala, Glu or Aib;
- A^{23} is Gln, Asp, Asn or Glu;
- 25 A^{24} is Ala, Aib, Val, Abu, Tle or Acc;
- A^{25} is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, $\text{HN-CH}((\text{CH}_2)_n\text{-N}(\text{R}^{10}\text{R}^{11}))\text{-C(O)}$ or $\text{HN-CH}((\text{CH}_2)_e\text{-X}^3)\text{-C(O)}$;
- A^{26} is Lys, Arg, hArg, Orn, $\text{Lys}(\text{N}^{\epsilon}\text{-decanoyl})$, $\text{HN-CH}((\text{CH}_2)_n\text{-N}(\text{R}^{10}\text{R}^{11}))\text{-C(O)}$ or $\text{HN-CH}((\text{CH}_2)_e\text{-X}^3)\text{-C(O)}$;
- 30 A^{27} is Glu, Asp, Leu, Aib or Lys;
- A^{28} is Phe, 2-Pal, 3-Pal, 4-Pal, 1Nal, 2Nal, $(X^6, X^7, X^8, X^9, X^{10})$ Phe, Aic, Acc, Aib, Cha or Trp;
- A^{29} is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;
- A^{30} is Ala, Aib or Acc;

A³¹ is Trp, 2-Pal, 3-Pal, 4-Pal, 1Nal, 2Nal, Phe, Acc, Aib, (X⁶,X⁷,X⁸,X⁹,X¹⁰)Phe or Cha;

A³² is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, (X⁶,X⁷,X⁸,X⁹,X¹⁰)Phe or Ala;

A³³ is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or (X⁶,X⁷,X⁸,X⁹,X¹⁰)Phe;

A³⁴ is Lys, Arg, hArg, Orn, HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O) or HN-CH((CH₂)_e-X³)-C(O);

5 A³⁵ is β-Ala, D-Ala, Gaba, Ava, HN-(CH₂)_m-C(O), Aib, Acc, D-Arg, a D-amino acid or deleted;

A³⁶ is L- or D-Arg, D- or L-Lys, or Lys(N^ε-decanoyl) or Lys(N^ε-dodecanoyl) or D- or L-hArg, D- or L-Orn or HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O), HN-CH((CH₂)_e-X³)-C(O), or deleted;


A³⁷ is Gly, β-Ala, Gaba, Aib, Acc, Act, Apc, Aun, Ava, Pro, Dhp, Dmt, Pip, ~~3-Hpr, 4-Hpr~~, L- or D-Arg, L- or D- Asp or Glu, Lys(N^ε-decanoyl), Lys(N^ε-dodecanoyl), Lys(N^ε-octanoyl), Lys(N^ε-

10 tetradecanoyl), Ser(O-decanoyl), or deleted;

A³⁸ is D- or L- His, L- or D-Ala, Asn, Gln, Ser, Thr, Acc, Ado, Aib, Apc, Act, Arg, Ava, Gly, β-Ala, Gaba, ~~HN-(CH₂)₆-C(O)~~ HN-(CH₂)_m-C(O), or deleted;

A³⁹ is D- or L- His, L- or D-Ala, Asn, Gln, Ser, Thr, Acc, Ado, Aib, Apc, Act, Arg, Aun, Gly, β-Ala, Gaba, Lys(N^ε-octanoyl), ~~HN-(CH₂)₆-C(O)~~ HN-(CH₂)_m-C(O), or deleted;

15 R¹ is OH, NH₂; (C₁-C₃₀)alkoxy, or NH-X²-CH₂-Z⁰, wherein X² is a (C₀-C₂₀)hydrocarbon moiety and Z⁰ is H, OH, CO₂H or CONH₂;



or -C(O)-NHR¹², wherein X⁴ is, independently for each occurrence, -C(O)-, -NH-C(O)- or -CH₂-, and wherein f is, independently for each occurrence, an integer from 1 to 29 inclusive;

20 X⁶,X⁷,X⁸,X⁹,X¹⁰ for each occurrence is independently selected from the group consisting of H, (C₁-C₆)alkyl, OH, OR⁴, NO₂, CN, and halo;

R⁴ is (C₁-C₃₀)alkyl, (C₂-C₃₀)alkenyl, phenyl(C₁-C₃₀)alkyl, naphthyl(C₁-C₃₀)alkyl, hydroxy(C₁-C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl, hydroxyphenyl(C₁-C₃₀)alkyl or hydroxynaphthyl(C₁-C₃₀)alkyl;

Z¹,Z²,Z³,Z⁴,Z⁵ for each occurrence is independently selected from the group consisting of

25 H, (C₁-C₆)alkyl, OH, OR⁴, NO₂, CN, and halo; Z¹ and Z² can ~~joint~~ join together to form a ring system;


e is, independently for each occurrence, an integer from 1 to 4 inclusive;

m is, independently for each occurrence, an integer from 5 to 24 inclusive;

n is, independently for each occurrence, an integer from 1 to 5, inclusive;

30 t is, independently for each occurrence, an integer from 0 to 4, inclusive;

each of R¹⁰ and R¹¹ is, independently for each occurrence, H, (C₁-C₃₀)alkyl, (C₁-C₃₀)acyl, (C₁-




C₃₀)alkylsulfonyl, -C((NH)(NH₂)) or ; and

R¹² and R¹³ each is, independently for each occurrence, (C₁-C₃₀)alkyl;

provided that:

- 5 R⁷ is not C(O)X¹¹, wherein X¹¹ is phenyl(C₁-C₃₀)alkyl, naphthyl(C₁-C₃₀)alkyl, hydroxy(C₁-C₃₀)alkyl, hydroxy(C₂-C₃₀)alkenyl, hydroxyphenyl(C₁-C₃₀)alkyl or hydroxynaphthyl(C₁-C₃₀)alkyl;

when R¹⁰ is (C₁-C₃₀)acyl, (C₁-C₃₀)alkylsulfonyl, -C((NH)(NH₂)) or



, then R¹¹ is H or (C₁-C₃₀)alkyl;

- 10 or a pharmaceutically acceptable salt thereof.


A preferred group of compounds of the immediately foregoing compound is where A¹¹ is Thr; A¹³ is Thr; A¹⁵ is Asp; A¹⁷ is Ser; A¹⁸ is Ser or Lys; A²¹ is Glu; A²³ is Gln or Glu; A²⁷ is Glu, Leu, Aib or Lys; and A³¹ is Trp, Phe, 1Nal or 2Nal; or a pharmaceutically acceptable salt thereof.

- 15 A preferred group of compounds of the immediately foregoing group of compounds is where A⁷ is 4-imidazol-carbonyl, 4-nitrophenyl-acetyl, 3-chloro-4-hydroxyphenyl-acetyl, 4-hydroxyphenyl-acetyl, 3-(4-aminophenyl)-propionyl, 3-(4-nitrophenyl)-propionyl, 3-(3,4-difluorophenyl)-propionyl, 3-fluoro-4-hydroxyphenyl-acetyl or 4-aminophenyl-acetyl; A⁹ is Glu, N-Me-Glu or N-Me-Asp; A¹² is Phe, Acc, 1Nal, 2Nal or Aic; A¹⁶ is Val, Acc or Aib; A¹⁹ is Tyr, 1Nal or 2Nal; A²⁰ is Leu, Acc or Cha; A²⁴ is Ala, Aib or Acc; A²⁵ is Ala, Aib, Acc, Lys, Arg, hArg, Orn, 20 HN-CH((CH₂)_n-N(R¹⁰R¹¹))-C(O) or HN-CH((CH₂)_e-X³)-C(O); A²⁸ is Phe, 1Nal or 2Nal; A²⁹ is Ile or Acc; A³⁰ is Ala or Aib; A³² is Leu, Acc or Cha; and A³³ is Val, Lys or Acc; or a pharmaceutically acceptable salt thereof.

- 25 A preferred group of compounds of the immediately foregoing group of compounds is where A⁸ is Ala, Gly, Ser, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A¹⁰ is Gly; A¹² is Phe, 1Nal, 2Nal, A6c or A5c; A¹⁶ is Val, A6c or A5c; A²⁰ is Leu, A6c, A5c or Cha; A²² is Gly, β-Ala, Glu or Aib; A²⁴ is Ala or Aib; A²⁹ is Ile, A6c or A5c; A³² is Leu, A6c, A5c or Cha; A³³ is Val, Lys, A6c or A5c; A³⁵ is Aib, β-Ala, Ado, A6c, A5c, D-Arg, Acc or Gly; A³⁷ is Gly, Aib, β-Ala, D-Ala, Pro, Asp, Aun or D-Asp; A³⁸ is D- or L- His, Asn, Ser, Apc, Act, Gly, β-Ala or Gaba; and A³⁹ is Ser, Thr or Aib; or a pharmaceutically acceptable salt thereof.


A preferred group of compounds of the immediately foregoing group of compounds is where X^4 for each occurrence is $-C(O)-$; and R^1 is OH or NH_2 ; or a pharmaceutically acceptable salt thereof.

A preferred compound of the formula (II) is where A^8 is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A^{10} is Gly; A^{12} is Phe, 1Nal, 2Nal, A6c or A5c; A^{16} is Val, A6c or A5c; A^{20} is Leu, A6c, A5c or Cha; A^{22} is Gly, β -Ala, Glu or Aib; A^{24} is Ala or Aib; A^{29} is Ile, A6c or A5c; A^{32} is Leu, A6c, A5c or Cha; A^{33} is Val, Lys, A6c or A5c; A^{35} is Aib, β -Ala, Ado, A6c, A5c D-Arg or Gly; and A^{37} is Gly, Aib, β -Ala, D-Ala, Pro or D-Asp; A^{38} is D- or L- His, Asn, Ser, Gly, β -Ala or Gaba; and A^{39} is Ser, or deleted; X^4 for each occurrence is $-C(O)-$; e for each occurrence is independently 1 or 2; R^1 is OH or NH_2 ; R^{10} is (C_1-C_{30}) acyl, (C_1-C_{30}) alkylsulfonyl or



, and R^{11} is H; or a pharmaceutically acceptable salt thereof.

More preferred of the immediately foregoing compounds is where R^{10} is (C_4-C_{20}) acyl,



(C_4-C_{20}) alkylsulfonyl or , or a pharmaceutically acceptable salt thereof.

A more preferred compound of formula (II) is where said compound is of the formula:

$(4Hppa^7)GLP-1(7-36)NH_2$; (SEQ ID NO:28)

$(3Hppa^7)GLP-1(7-36)NH_2$; (SEQ ID NO:29)

$(phenylacetyl^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:30)

$((3-fluoro-4-hydroxyphenyl-acetyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:31)

$((4-imidazol-carbonyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:32)

$((4-nitrophenyl-acetyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:33)

$((3-chloro-4-hydroxyphenyl-acetyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:34)

$((4-hydroxyphenylacetyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:35)

$((4-aminophenyl-acetyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:36)

$((3-(3-hydroxyphenyl)-propionyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:37)

$((3-phenyl-propionyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:38)

$((3-(4-aminophenyl)-propionyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:39)

$((3-(4-nitrophenyl)-propionyl)^7)hGLP-1(7-36)NH_2$; (SEQ ID NO:40)

((3-(2-hydroxyphenyl)-propionyl)⁷)hGLP-1(7-36) NH₂; (SEQ ID NO:41)
((3-(3,4-difluorophenyl)-propionyl)⁷)hGLP-1(7-36) NH₂; (SEQ ID NO:42) or
((3-(2,4-dihydroxyphenyl)-propionyl)⁷)hGLP-1(7-36) NH₂; (SEQ ID NO:43)
or a pharmaceutically acceptable salt thereof.

5 A more preferred compound of formula (II) is where said compound is the pharmaceutically acceptable salt thereof.

Another more preferred compound of formula (I) or (II) is each of the compounds that are specifically enumerated hereinbelow in the Examples section of the present disclosure, or a pharmaceutically acceptable salt thereof.

10 In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or (II) as defined hereinabove or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

In yet another aspect, the present invention provides a method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said
15 subject an effective amount of a compound of formula (I) or (II) as defined hereinabove or a pharmaceutically acceptable salt thereof.


In a further aspect, the present invention provides a method of treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous
20 system disease, restenosis, neurodegenerative disease, renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, hypertension, treatment of respiratory distress (U.S. Patent Application Publication No. 2004/0235726 A1) and disorders wherein the reduction of food intake is desired, in a subject in need thereof which comprises administering to said
25 subject an effective amount of a compound of formula (I) or (II) as defined hereinabove or a pharmaceutically acceptable salt thereof. A preferred method of the immediately foregoing method is where the disease being treated is Type I diabetes or Type II diabetes. GLP-1 analogues of the present invention that elicit an antagonist effect from a subject can be used for treating the following: hypoglycemia and malabsorption syndrome associated with gastroectomy or small bowel resection.

30 With the exception of the N-terminal amino acid, all abbreviations (e.g. Ala) of amino acids in this disclosure stand for the structure of -NH-CH(R)-CO-, wherein R and R' each is, independently, hydrogen or the side chain of an amino acid (e.g., R = CH₃ and R' = H for Ala) or R and R' may be joined to form a ring system. For the N-terminal amino acid, the abbreviation

stands for the structure of $=N-C(R)(R')-CO-$, wherein "=" represents the bonds to R^2 and R^3 , defined herein. R^2 and R^3 are as defined above, except when A^7 is Ura, Paa or Pta, in which case R^2 and R^3 are not present since Ura, Paa and Pta are considered here as des-amino amino acids.

5 The application employs the following commonly understood abbreviations:

Abu	α -aminobutyric acid
Acc	1-amino-1-cyclo(C_3 - C_9)alkyl carboxylic acid
A3c	1-amino-1-cyclopropanecarboxylic acid
A4c	1-amino-1-cyclobutanecarboxylic acid
10 A5c	1-amino-1-cyclopentanecarboxylic acid
A6c	1-amino-1-cyclohexanecarboxylic acid
Act	4-amino-4-carboxytetrahydropyran
Ado	12-aminododecanoic acid
Aec	4-(2-aminoethyl)-1-carboxymethyl-piperazine



15 (i.e., the structure:)

Aib	α -aminoisobutyric acid
Aic	2-aminoindan-2-carboxylic acid
Ala or A	alanine
20 β -Ala	beta-alanine
Amp	4-amino-phenylalanine;
Apc	4-amino-4-carboxypiperidine:
Arg or R	arginine
hArg	homoarginine
25 Asn or N	asparagine
Asp or D	aspartic acid
Aun	11-aminoundecanoic acid
Ava	5-aminovaleric acid
Cha	β -cyclohexylalanine
30 Dhp	3,4-dehydroproline
Dmt	5,5-dimethylthiazolidine-4-carboxylic acid
Gaba	γ -aminobutyric acid
Gln or Q	glutamine
Glu or E	glutamic acid
35 Gly or G	glycine
His or H	histidine
4Hppa	3-(4-hydroxyphenyl)propionic acid
3Hppa	3-(3-hydroxyphenyl)propionic acid
3Hyp	trans-3-hydroxy-L-proline
40 (i.e., (2S, 3S)-3-hydroxypyrrolidine-2-carboxylic acid)	
4Hyp	4-hydroxyproline
(i.e., (2S, 4R)-4-hydroxypyrrolidine-2-carboxylic acid)	
Ile or I	isoleucine

	Leu or L	leucine
	Lys or K	lysine
	1Nal	β -(1-naphthyl)alanine
	2Nal	β -(2-naphthyl)alanine
5	Nle	norleucine
	N-Me-Ala	N-methyl-alanine;
	N-Me-Asp	N-methyl-aspartic acid
	N-Me-Glu	N-methyl-glutamic acid;
	N-Me-Gly	N-methyl-glycine;
10	Nva	norvaline
	Orn	ornithine
	Paa	<i>trans</i> -3-(3-pyridyl) acrylic acid;
	2Pal	β -(2-pyridinyl)alanine
	3Pal	β -(3-pyridinyl)alanine
15	4Pal	β -(4-pyridinyl)alanine
	Phe or F	phenylalanine
	(3,4,5F)Phe	3,4,5-trifluorophenylalanine
	(2,3,4,5,6)Phe	2,3,4,5,6-pentafluorophenylalanine
	Pip	pipecolic acid
20	Pro or P	proline
	Pta	(4-pyridylthio) acetic acid;
	Ser or S	serine
	Thr or T	threonine
	Tle	tert-leucine
25	Tma-His	N,N-tetramethylamidino-histidine;
	Trp or W	tryptophan
	Tyr or Y	tyrosine
	Ura	urocanic acid.
	Val or V	valine

30


Certain other abbreviations used herein are defined as follows:

	2BrZ	2-bromobenzyloxycarbonyl
	2ClZ	2-chlorobenzyloxycarbonyl
35	Boc:	<i>tert</i> -butyloxycarbonyl
	Bzl:	benzyl
	DCM:	dichloromethane
	DIC:	N, N-diisopropylcarbodiimide
	DIEA:	diisopropylethyl amine
40	Dmab:	4-{N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)-amino} benzyl
	DMAP:	4-(dimethylamino)pyridine
	DMF	dimethylformamide
	DNP:	2,4-dinitrophenyl
45	Fm	formyl
	Fmoc:	9-Fluorenylmethyloxycarbonyl
	HBTU:	2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
	cHex	cyclohexyl
50	HF	hydrogen fluoride,


HOAT:	O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HOBt:	1-hydroxy-benzotriazole
Mmt:	4-methoxytrityl
NMP:	N-methylpyrrolidone
OcHex	O-cyclohexyl
PAM resin	4-hydroxymethylphenylacetamidomethyl resin
Pbf:	2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
tBu:	tert-butyl
TIS:	triisopropylsilane
TOS:	tosyl
trt	trityl
TFA:	trifluoro acetic acid
TFFH:	tetramethylfluoroforamidinium hexafluorophosphate
Xan	xanthyl
Z:	benzyloxycarbonyl

In the above formula, hydroxyalkyl, hydroxyphenylalkyl, and hydroxynaphthylalkyl may contain 1-4 hydroxy substituents. COX⁵ stands for -C=O·X⁵. Examples of -C=O·X⁵ include, but are not limited to, acetyl and phenylpropionyl.


What is meant by Lys(N^E-alkanoyl) is represented by the following structure:



What is meant by Lys(N^E-alkylsulfonyl) is represented by the following structure:




What is meant by Lys(N^E-(2-(4-alkyl-1-piperazine)-acetyl)) is represented by the following




structure:

What is meant by Asp(1-(4-alkyl-piperazine)) is represented by the following




structure:

What is meant by Asp(1-alkylamino) is represented by the following




5 structure:

What is meant by Lys(N^ε-Aec-alkanoyl) is represented by the structure:



The variable n in the foregoing structures is 1-30. Lys(N^ε-Aec-alkanoyl) is represented by the structure:



The term "halo" encompasses fluoro, chloro, bromo and iodo.

The term "(C₁-C₃₀)hydrocarbon moiety" encompasses alkyl, alkenyl and alkynyl, and in the case of alkenyl and alkynyl there are C₂-C₃₀.

A peptide of this invention is also denoted herein by another format, e.g., (A5c⁸)hGLP-1(7-36)NH₂; with the substituted amino acids from the natural sequence placed between the first set of parentheses (e.g., A5c⁸ for Ala⁸ in hGLP-1). The abbreviation GLP-1 means glucagon-like peptide-1; hGLP-1 means human glucagon-like peptide-1. The numbers between the parentheses refer to the number of amino acids present in the peptide (e.g., hGLP-1(7-36) is amino acids 7 through 36 of the peptide sequence for human GLP-1). The sequence for hGLP-1(7-37) is listed in Mojsov, S., Int. J. Peptide Protein Res., 40, 1992, pp. 333-342. The designation "NH₂" in hGLP-1(7-36)NH₂ indicates that the C-terminus of the peptide is amidated. hGLP-1(7-36) means that the C-terminus is the free acid. In hGLP-1(7-38), residues in positions 37 and 38 are Gly and Arg, respectively.

Detailed Description

The peptides of this invention can be prepared by standard solid phase peptide synthesis. See, e.g., Stewart, J.M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed. 1984). The substituents R² and R³ of the above generic formula may be attached to the free amine of the N-terminal amino acid by standard methods known in the art. For example, alkyl groups, e.g., (C₁-C₃₀)alkyl, may be attached using reductive alkylation. Hydroxyalkyl groups, e.g., (C₁-C₃₀)hydroxyalkyl, may also be attached using reductive alkylation wherein the free hydroxy group is protected with a t-butyl ester. Acyl groups, e.g., COE¹, may be attached by coupling the free acid, e.g., E¹COOH, to the free amine of the N-terminal amino acid by mixing the completed resin with 3 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for one hour. If the free acid contains a free hydroxy group, e.g., 3-fluoro-4-hydroxyphenylacetic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBt.

When R¹ is NH-X²-CH₂-CONH₂; (i.e., Z⁰=CONH₂), the synthesis of the peptide starts with BocHN-X²-CH₂-COOH which is coupled to the MBHA resin. If R¹ is NH-X²-CH₂-COOH, (i.e., Z⁰=COOH) the synthesis of the peptide starts with Boc-HN-X²-CH₂-COOH which is coupled to PAM resin. For this particular step, 4 molar equivalents of Boc-HN-X²-COOH, HBTU and HOBt and 10 molar equivalents of DIEA are used. The coupling time is about 8 hours.

In the synthesis of a GLP-1 analogue of this invention containing A5c, A6c, and/or Aib, the coupling time is 2 hrs for these residues and the residue immediately following them.

The substituents R^2 and R^3 of the above generic formula can be attached to the free amine of the N-terminal amino acid by standard methods known in the art. For example, alkyl groups, e.g., (C_1-C_{30}) alkyl, can be attached using reductive alkylation. Hydroxyalkyl groups, e.g., (C_1-C_{30}) hydroxyalkyl, can also be attached using reductive alkylation wherein the free hydroxy group is protected with a t-butyl ester. Acyl groups, e.g., COX^5 , can be attached by coupling the free acid, e.g., X^5COOH , to the free amine of the N-terminal amino acid by mixing the completed resin with 3 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for about one hour. If the free acid contains a free hydroxy group, e.g., 3-fluoro-4-hydroxyphenylacetic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBT.

The peptides of this invention can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids). A typical method of making a salt of a peptide of the present invention is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide of the present invention (the TFA salt results from the purification of the peptide by using preparative HPLC, eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax, 300 SB, C-8). The column is eluted with (1) 0.1N ammonium acetate aqueous solution for 0.5 hrs, (2) 0.25N acetic acid aqueous solution for 0.5 hrs and (3) a linear gradient (20% to 100% of solution B over 30 min) at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; solution B is 0.25N acetic acid in acetonitrile/water, 80:20). The fractions containing the peptide are collected and lyophilized to dryness.

As is well known to those skilled in the art, the known and potential uses of GLP-1 is varied and multitudinous (See, Todd, J.F., et al., Clinical Science, 1998, 95, pp. 325-329; and Todd, J.F. et al., European Journal of Clinical Investigation, 1997, 27, pp.533-536). Thus, the administration of the compounds of this invention for purposes of eliciting an agonist effect can have the same effects and uses as GLP-1 itself. These varied uses of GLP-1 may be summarized as follows, treatment of: Type I diabetes, Type II diabetes, obesity, glucagonomas,

secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system diseases, restenosis, neurodegenerative diseases, renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, hypertension, treatment of respiratory distress (U.S. Patent Application Publication No. 2004/0235726 A1), and disorders wherein the reduction of food intake is desired. GLP-1 analogues of the present invention that elicit an antagonist effect from a subject can be used for treating the following: hypoglycemia and malabsorption syndrome associated with gastroectomy or small bowel resection.

Accordingly, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of formula (I) or (II) in association with a pharmaceutically acceptable carrier.

The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. In general, an effective dosage for the activities of this invention is in the range of 1×10^{-7} to 200 mg/kg/day, preferably 1×10^{-4} to 100 mg/kg/day, which can be administered as a single dose or divided into multiple doses.

The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration include, without limitation, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, and the like, containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.

Preparations according to this invention for parenteral administration include, without limitation, sterile aqueous or non-aqueous solutions, suspensions, emulsions, and the like. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl
5 oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile
10 injectable medium immediately before use.

Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.

Compositions for nasal or sublingual administration are also prepared with standard
15 excipients well known in the art.

Further, a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a
20 bioactive agent in a gelable form. U.S. Patent No. 5,821,221, teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. U.S. Patent No. 5,916,883 teaches sustained release compositions comprising a bioactive agent and cyclodextrin. PCT Publication WO99/38536 teaches absorbable sustained release compositions of a bioactive agent. PCT Publication WO00/04916 teaches a process for making microparticles comprising a
25 therapeutic agent such as a peptide in an oil-in-water process. PCT Publication WO00/09166 teaches complexes comprising a therapeutic agent such as a peptide and a phosphorylated polymer. PCT Publication WO00/25826 teaches complexes comprising a therapeutic agent such as a peptide and a polymer bearing a non-polymerizable lactone.

Unless defined otherwise, all technical and scientific terms used herein have the same
30 meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents and other references mentioned herein are hereby incorporated by reference, each in its entirety.

The following examples describe synthetic methods for making a peptide of this invention, which methods are well-known to those skilled in the art. Other methods are also known to those skilled in the art. The examples are provided for the purpose of illustration and are not meant to limit the scope of the present invention in any manner.

Boc- β Ala-OH, Boc-D-Arg(Tos)-OH and Boc-D-Asp(OcHex) were purchased from Nova Biochem, San Diego, California. Boc-Aun-OH was purchased from Bachem, King of Prussia, PA. Boc-Ava-OH and Boc-Ado-OH were purchased from Chem-Impex International, Wood Dale, IL. Boc-Nal-OH was purchased from Synthetech, Inc. Albany, OR.

Example 1

((3-fluoro-4-hydroxyphenyl-acetyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:31)

The title peptide, also referred to herein as ((3F, 4HO)-phenylacetyl⁷)hGLP-1(7-36)NH₂; was synthesized on an Applied Biosystems model 433A peptide synthesizer (Foster City, CA) using Fluorenylmethyloxycarbonyl (Fmoc) chemistry. A Rink Amide-4-methylbenzylhydramine (MBHA) resin (Novabiochem., San Diego, CA) with substitution of 0.66 mmol/g was used. The Fmoc amino acids (AnaSpec, San Jose, CA) used were Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(Boc)-OH, and Fmoc-Val-OH. The last residue coupled to the resin was 3-Fluoro-4-hydroxyphenylacetic acid (Aldrich, Milwaukee, WI.). The synthesis was carried out on a 0.1 mmol scale. The Fmoc groups were removed by treatment with 20% piperidine in N-methylpyrrolidone (NMP) for 30 min. In each coupling step, the Fmoc amino acid (3 eq, 0.3 mmol) was first pre-activated in 2 ml solution of 0.45M 2-(1H-benzotriazole-1-yl)-1,1,2,3-tetramethyluronium hexafluorophosphate/1-hydroxy-benzotriazole (HBTU/HOBT) in NMP. This activated amino acid ester, 1 ml of diisopropylethylamine (DIEA) and 1 ml of NMP were added to the resin. The ABI 433A peptide synthesizer was programmed to perform the following reaction cycle: (1) washing with NMP, (2) removing Fmoc protecting group with 20% piperidine in NMP for 30 min, (3) washing with NMP, (4) coupling with pre-activated Fmoc amino acid for 1h. The resin was coupled successively according to the sequence of the title peptide. After the peptide chain was assembled the resin was washed completely by using *N,N*-dimethylformamide (DMF) and dichloromethane (DCM).

At the end of the assembly of the peptide chain, the peptide-resin was transferred to a reaction vessel on a shaker and treated with a mixture of TFA, H₂O and triisopropylsilane (TIS) (9.5 ml / 0.85 ml / 0.8 ml) for 4h. The resin was filtered off and the filtrate was poured into 200

ml of ether. The precipitate was collected by filtration and washed thoroughly with ether. This crude product was dissolved in a mixture of acetonitrile and aqueous acetic acid solution and purified on a reverse-phase preparative HPLC system with a column (4 x 43 cm) of C₁₈ DYNAMAX-100 A⁰ (Varian, Walnut Creek, CA). The column was eluted over approximately 1
5 hour using a linear gradient of 90% A:10% B to 50% A:50% B, where A was 0.1% TFA in water and B was 0.1% TFA in acetonitrile. The fractions were checked by analytical HPLC and those containing pure product were pooled and lyophilized to dryness to give 5.6 mg (1.7% yield) of a white solid. Purity was checked by using an analytical HPLC system and found to be 95.1%. Electro-spray ionization mass spectrometry (ESI-MS) analysis gave the molecular weight at
10 3312.3 (in agreement with the calculated molecular weight of 3312.6).

Example 2

(Aib^{8,35}, Arg^{26,34}, Phe³¹, Pro³⁷, Ser^{38, 39})hGLP-1(7-39)-NH₂ (SEQ ID NO:1)

The title compound was synthesized substantially according to the procedure
15 described for Example 1 using the appropriate protected amino acids (AnaSpec, San Jose, CA). At the end of the assembly of the protected peptide chain, an additional step was added to remove the N-terminal Fmoc- protecting group by using 20% piperidine in NMP for 30 min. The peptide resin was then washed, cleaved, purified and characterized using the procedures described for Example 1. Yield was 7.9%. Purity was 95.0%. Electro-spray ionization mass
20 spectrometry (ESI-MS) analysis gave the molecular weight at 3629.40 (in agreement with the calculated molecular weight of 3628.00).

The following examples can be made according to the appropriate procedures described hereinabove:

25 Example 3 (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Asn³⁸)hGLP-1(7-38)-NH₂ (SEQ ID NO:2)

Example 4 ((4-imidazol-carbonyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:32)

Example 5 ((3-(3-hydroxyphenyl)-propionyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:37)

Example 6 ((3-phenyl-propionyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:38)

Example 7 ((4-nitrophenyl-acetyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:33)

30 Example 8 ((3-chloro-4-hydroxyphenyl-acetyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:34)

Example 9 ((4-hydroxyphenylacetyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:35)

Example 10 (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Ser³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:3)

Example 11 (Aib^{8,35,37}, Gaba³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:4)

- Example 12 (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, His³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:5)
- Example 13 (Aib^{8,35}, Arg^{26,34}, Phe³¹, β-Ala³⁷, His³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:6)
- Example 14 (Aib^{8,35,37}, Arg^{26,34}, D-His³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:7)
- Example 15 (Aib^{8,35,37}, β-Ala³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:8)
- 5 Example 16 ((3-(4-aminophenyl)-propionyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:39)
- Example 17 ((3-(4-nitrophenyl)-propionyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:40)
- Example 18 ((3-(2-hydroxyphenyl)-propionyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:41)
- Example 19 ((3-(3,4-difluorophenyl)-propionyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:42)
- Example 20 (Aib^{8,35}, Arg^{26,34}, β-Ala³⁷, His³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:9)
- 10 Example 21 (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Gly³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:10)
- Example 22 (Aib^{8,35,37}, Arg^{26,34}, Gly³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:11)
- Example 23 (Aib^{8,35,37}, Arg^{26,34}, β-Ala³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:12)
- Example 24 (Aib^{8,35,37}, Arg^{26,34}, Gaba³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:13)
- Example 25 (Aib^{8,35,37}, Arg³⁴, Phe³¹, His³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:14)
- 15 Example 26 (Aib^{8,35,37}, Arg^{26,34}, His³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:15)
- Example 27 (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Gaba³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:16)
- Example 28 (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, Ava³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:17)
- Example 29 (Aib^{8,35,37}, Arg^{26,34}, Ava³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:18)
- Example 30 (Aib^{8,35,37}, Arg³⁴, Phe³¹, D-His³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:19)
- 20 Example 31 (Aib^{8,35,37}, Arg³⁴, Phe³¹, Gly³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:20)
- Example 32 ((4-aminophenyl-acetyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:36)
- Example 33 (Aib^{8,35,37}, Gly³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:21)
- Example 34 (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, D-His³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:22)
- Example 35 (Aib^{8,35}, Arg^{26,34}, Phe³¹, β-Ala³⁷, D-His³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:23)
- 25 Example 36 (Aib^{8,35,37}, Arg^{26,34}, Phe³¹, β-Ala³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:24)
- Example 37 (Aib^{8,35}, Arg^{26,34}, Phe³¹, β-Ala^{37,38})hGLP-1(7-38)NH₂ (SEQ ID NO:25)
- Example 38 (Aib^{8,35,37}, Arg³⁴, Phe³¹, β-Ala³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:26)
- Example 39 (Aib^{8,35,37}, Arg³⁴, Phe³¹, Gaba³⁸)hGLP-1(7-38)NH₂ (SEQ ID NO:27)
- Example 40 ((3-(2,4-dihydroxyphenyl)-propionyl)⁷)hGLP-1(7-36)NH₂ (SEQ ID NO:43)

30

Physical data for a representative sampling of the compounds exemplified herein are given in Table 1.

Table 1.

Example Number	Molecular Weight Calculated	Molecular Weight MS(ES)	Purity (%) (HPLC)
1	3312.60	3312.30	95.1
2	3628.00	3629.40	95.0
3	3555.94	3556.50	99.0
4	3254.59	3254.50	97.0
5	3308.68	3309.60	99.0
6	3292.68	3392.50	99.0
7	3323.65	3323.60	96.0
8	3329.10	3329.00	97.2
9	3294.65	3294.50	99.0
10	3528.91	3532.9	97.5
11	3509.95	3509.33	97.7
12	3578.98	3579.20	99.9
13	3564.95	3565.05	99.9
14	3618.01	3618.20	99.9
15	3495.92	3495.60	99.9
16	3307.69	3307.90	99.0
17	3337.68	3337.40	97.0
18	3308.68	3308.60	98.0
19	3328.66	3328.50	97.0
20	3603.99	3603.86	99.3
21	3498.89	3499.29	99.9
22	3537.92	3538.19	97.4
23	3551.95	3552.80	99.9
24	3565.98	3565.62	99.9
25	3550.96	3550.90	99.9
26	3618.01	3618.00	97.0
27	3526.94	3527.20	99.9
28	3540.97	3540.30	99.1
29	3580.01	3579.94	96.7
30	3550.96	3550.89	99.9

31	3470.87	3471.16	99.9
32	3293.67	3293.80	99.0
33	3481.90	3481.80	95.8
34	3578.90	3578.70	98.6
35	3564.95	3564.30	99.9
36	3512.91	3512.54	99.9
37	3498.89	3498.95	99.9
38	3484.90	3484.75	99.9
39	3498.93	3498.87	96.8
40	3324.68	3324.38	98.6

A compound of the present invention can be tested for activity as a GLP-1 binding compound according to the following procedure.

Cell Culture:

- 5 RIN 5F rat insulinoma cells (ATCC-# CRL-2058, American Type Culture Collection, Manassas, VA), expressing the GLP-1 receptor, were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, and maintained at about 37 °C in a humidified atmosphere of 5% CO₂/95% air.

Radioligand Binding:

- 10 Membranes were prepared for radioligand binding studies by homogenization of the RIN cells in 20 ml of ice-cold 50 mM Tris-HCl with a Brinkman Polytron (Westbury, NY) (setting 6, 15 sec). The homogenates were washed twice by centrifugation (39,000 g / 10 min), and the final pellets were resuspended in 50 mM Tris-HCl, containing 2.5 mM MgCl₂, 0.1 mg/ml bacitracin (Sigma Chemical, St. Louis, MO), and 0.1% BSA. For assay, aliquots (0.4 ml) were incubated
- 15 with 0.05 nM (¹²⁵I)GLP-1(7-36) (~2200 Ci/mmol, New England Nuclear, Boston, MA), with and without 0.05 ml of unlabeled competing test peptides. After a 100 min incubation (25 °C), the bound (¹²⁵I)GLP-1(7-36) was separated from the free by rapid filtration through GF/C filters (Brandel, Gaithersburg, MD), which had been previously soaked in 0.5% polyethyleneimine. The filters were then washed three times with 5 ml aliquots of ice-cold 50 mM Tris-HCl, and the
- 20 bound radioactivity trapped on the filters was counted by gamma spectrometry (Wallac LKB, Gaithersburg, MD). Specific binding was defined as the total (¹²⁵I)GLP-1(7-36) bound minus that bound in the presence of 1000 nM GLP1(7-36) (Bachem, Torrence, CA).